**Supplemental Content (Additional References)**

31s. Low N, et al. **Global control of sexually transmitted infections**. *Lancet* 2006; 368(9551):2001-2016.

32s. Centers for Disease Control and Prevention. **Legal Status of Expedited Partner Therapy (EPT).** <https://www.cdc.gov/std/ept/legal/default.htm> 2017.Accessed on July 31, 2019.

33s. Alam N, et al. **Partner notification for sexually transmitted infections in developing countries: a systematic review.** *BMC Public Health* 2010; 10(19).

34s. Ferreira A, et al. **Strategies for partner notification for sexually transmitted infections, including HIV**. *The Cochrane database of systematic reviews* 2013; (10):Cd002843.

35s. Taleghani S, et al. **Acceptability and efficacy of partner notification for curable sexually transmitted infections in sub-Saharan Africa: A systematic review**. *Int J STD AIDS* 2018; 30(3): 292-303.

36s. Cristillo AD, et al. **Point-of-Care Sexually Transmitted Infection Diagnostics: Proceedings of the STAR Sexually Transmitted Infection-Clinical Trial Group Programmatic Meeting**. *Sex Transm Dis* 2017; 44(4):211-218.

37s. Schwebke J, et al. **Positive screening tests for gonorrhea and chlamydial infection fail to lead consistently to treatment of patients attending a sexually transmitted disease clinic.** *Sex Transm Dis* 1997; 24(181-4).

38s. Shannon CL, et al. **Acceptability and Feasibility of Rapid Chlamydial, Gonococcal, and Trichomonal Screening and Treatment in Pregnant Women in 6 Low- to Middle-Income Countries**. *Sex Transm Dis* 2018; 45(10):673-676.

39s. Ong JJ, et al. **Chlamydia screening for pregnant women aged 16-25 years attending an antenatal service: a cost-effectiveness study**. *BJOG* 2016; 123(7):1194-1202.

40s. Ditkowsky J, et al. **Cost-benefit analysis of Chlamydia trachomatis screening in pregnant women in a high burden setting in the United States**. *BMC infectious diseases* 2017; 17(1):155.

41s. Kahn JG, et al. **The cost and cost-effectiveness of scaling up screening and treatment of syphilis in pregnancy: a model**. *PLoS One* 2014; 9(1):e87510.

42s. Shahrook S, et al. **Strategies of testing for syphilis during pregnancy**. *The Cochrane database of systematic reviews* 2014; (10):Cd010385.

43s. Bonawitz RE, et al. **Assessment of the impact of rapid syphilis tests on syphilis screening and treatment of pregnant women in Zambia**. *Int J Gynaecol Obstet* 2015; 130 Suppl 1:S58-62.

44s. Bristow CC, et al. **Cost-effectiveness of HIV and syphilis antenatal screening: a modeling study**. *Sex Transm Infect* 2016; 92(5):340-346.

45s. Mayer KH, Venkatesh KK. **Interactions of HIV, other sexually transmitted diseases, and genital tract inflammation facilitating local pathogen transmission and acquisition**. *American journal of reproductive immunology* 2011; 65(3):308-316.

46s. Goldenberg RL, et al. **Epidemiology and causes of preterm birth**. *Lancet* 2008; 371(9606):75-84.

47s. Presicce P, et al. **IL-1 signaling mediates intrauterine inflammation and chorio-decidua neutrophil recruitment and activation**. *JCI insight* 2018; 3(6).

48s. McDowell KM, et al. **Pulmonary Morbidity in Infancy after Exposure to Chorioamnionitis in Late Preterm Infants**. *Annals of the American Thoracic Society* 2016; 13(6):867-876.

49s. Stern DA, et al. **Poor airway function in early infancy and lung function by age 22 years: a non-selective longitudinal cohort study**. *Lancet* 2007; 370(9589):758-764.

50s. Berry CE, et al. **A Distinct Low Lung Function Trajectory from Childhood to the Fourth Decade of Life**. *Am J Respir Crit Care Med* 2016; 194(5):607-612.

51s. Taylor-Robinson D, Lamont RF. **Mycoplasmas in pregnancy**. *BJOG* 2011; 118(2):164-174.

52s. Lis R, et al. **Mycoplasma genitalium infection and female reproductive tract disease: a meta-analysis**. *Clinical infectious diseases* 2015; 61(3):418-426.

53s. Sena AC, et al. **A Silent Epidemic: The Prevalence, Incidence and Persistence of Mycoplasma genitalium Among Young, Asymptomatic High-Risk Women in the United States**. *Clinical infectious diseases* 2018; 67(1):73-79.

54s. Paukner S, et al. **In Vitro Activity of Lefamulin against Sexually Transmitted Bacterial Pathogens**. *Antimicrobial agents and chemotherapy* 2018; 62(5).

55s. Schooley RT. **The human microbiome: implications for health and disease, including HIV infection**. *Topics in antiviral medicine* 2018; 26(3):75-78.

56s. Muzny CA, et al. **Identification of Key Bacteria Involved in the Induction of Incident Bacterial Vaginosis: A Prospective Study**. *J Infect Dis* 2018; 218(6):966-978.

57s. Ravel J, et al. **Vaginal microbiome of reproductive-age women**. *Proceedings of the National Academy of Sciences of the United States of America* 2011; 108 Suppl 1:4680-4687.

58s. Verstraelen H, et al. **Longitudinal analysis of the vaginal microflora in pregnancy suggests that L. crispatus promotes the stability of the normal vaginal microflora and that L. gasseri and/or L. iners are more conducive to the occurrence of abnormal vaginal microflora**. *BMC microbiology* 2009; 9:116.

59s. Romero R, et al. **The composition and stability of the vaginal microbiota of normal pregnant women is different from that of non-pregnant women**. *Microbiome* 2014; 2(1):4.

60s. Romero R, et al. **The vaginal microbiota of pregnant women who subsequently have spontaneous preterm labor and delivery and those with a normal delivery at term**. *Microbiome* 2014; 2:18.

61s. DiGiulio DB, et al. **Temporal and spatial variation of the human microbiota during pregnancy**. *Proceedings of the National Academy of Sciences of the United States of America* 2015; 112(35):11060-11065.

62s. Hyman RW, et al. **Diversity of the vaginal microbiome correlates with preterm birth**. *Reproductive sciences* 2014; 21(1):32-40.

63s. Muzny CA, Schwebke JR. **Pathogenesis of Bacterial Vaginosis: Discussion of Current Hypotheses**. *J Infect Dis* 2016; 214 Suppl 1:S1-5.

64s. Van Der Pol WJ, et al. **In Silico and Experimental Evaluation of Primer Sets for Species-Level Resolution of the Vaginal Microbiota Using 16S Ribosomal RNA Gene Sequencing**. *J Infect Dis* 2019; 219(2):305-314.

65s. Centers for Disease Control and Prevention. **Sexually Transmitted Disease Surveillance 2017**. <https://www.cdc.gov/std/stats17/default.htm> 2017. Accessed on July 31, 2019.

66s. Centers for Disease Control and Prevention. **CDC Call to Action: Let’s Work Together to Stem the Tide of Rising Syphilis in the United States.** <https://npin.cdc.gov/publication/cdc-call-action-lets-work-together-stem-tide-rising-syphilis-us>2017. Accessed on July 31, 2019.

67s. Looker KJ, et al. **First estimates of the global and regional incidence of neonatal herpes infection**. *Lancet Glob Health* 2017; 5(3):e300-e309.

68s. Fanfair RN, et al. **Trends in seroprevalence of herpes simplex virus type 2 among non-Hispanic blacks and non-Hispanic whites aged 14 to 49 years--United States, 1988 to 2010**. *Sex Transm Dis* 2013; 40(11):860-864.

69s. Brown ZA, et al. **Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant**. *Jama* 2003; 289(2):203-209.

70s. Kimberlin D. **Herpes simplex virus infections of the newborn.** *Semin Perinatol* 2007; 31:19-25.

71s. Hollier L, Wendel G. **Third trimester antiviral prophylaxis for preventing maternal genital herpes simplex virus (HSV) recurrences and neonatal infection.** *Cochrane Database of Systematic Reviews* 2008; (1).

72s. Newman L, et al. **Global estimates of syphilis in pregnancy and associated adverse outcomes: analysis of multinational antenatal surveillance data**. *PLoS Med* 2013; 10(2):e1001396.

73s. Munkhuu B, et al. **One-stop service for antenatal syphilis screening and prevention of congenital syphilis in Ulaanbaatar, Mongolia: a cluster randomized trial**. *Sex Transm Dis* 2009; 36(11):714-720.

74s. Myer L, et al. **Impact of on-site testing for maternal syphilis on treatment delays, treatment rates, and perinatal mortality in rural South Africa: a randomised controlled trial**. *Sex Transm Infect* 2003; 79(3):208-213.

75s. Zhou P, et al. **A study evaluating ceftriaxone as a treatment agent for primary and secondary syphilis in pregnancy**. *Sex Transm Dis* 2005; 32(8):495-498.

76s. Nurse-Findlay S, et al. **Shortages of benzathine penicillin for prevention of mother-to-child transmission of syphilis: An evaluation from multi-country surveys and stakeholder interviews**. *PLoS Med* 2017; 14(12):e1002473.

77s. Heumann CL, et al. **Adverse Birth Outcomes and Maternal Neisseria gonorrhoeae Infection: A Population-Based Cohort Study in Washington State**. *Sex Transm Dis* 2017; 44(5):266-271.

78s. Centers for Disease Control and Prevention. **Gonorrhea - CDC fact sheet (detailed version)** In; 2015.

79s. Edwards L, et al. **Gonorrhea in pregnancy.** . *Am J Obstet Gynecol* 1978; 132(6):637–641.

80s. Silva M, et al. **Perinatal morbidity and mortality associated with chlamydial infection: a meta-analysis study.** *The Brazilian journal of infectious diseases* 2011; 15(6):533-539.

81s. Cotch MF, et al. **Trichomonas vaginalis associated with low birth weight and preterm delivery. The Vaginal Infections and Prematurity Study Group**. *Sex Transm Dis* 1997; 24(6):353-360.

82s. Klebanoff M, et al. **Failure of metronidazole to prevent preterm delivery among pregnant women with asymptomatic Trichomonas vaginalis infection.** *The New England journal of medicine* 2001; 345:487-493.

83s. van den Broek N. **Content and quality – integrated, holistic, one-stop antenatal care is needed for all**. *BJOG* 2016; 123(4):558-558.

84s. Global Alliance to Prevent Prematurity and Stillbirth. <https://www.gapps.org/>. Accessed on July 31, 2019.

85s. World Health Organization. **Antenatal Care for a Positive Pregnancy.** <https://www.who.int/reproductivehealth/publications/maternal_perinatal_health/anc-positive-pregnancy-experience/en/>2016. Accessed on July 31, 2019.